Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Zappacosta

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Biomolecular Screening|October 29, 2013
Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cellsHu Li, Wensheng Xie, Elizabeth R Gore, et al.
Scientific Reports|December 18, 2020
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissuesPaul B Noto, Timothy W Sikorski, Francesca Zappacosta, et al.
Frontiers in Immunology|October 17, 2022
Complement membrane attack complex is an immunometabolic regulator of NLRP3 activation and IL-18 secretion in human macrophagesGisela Jimenez-Duran, Joseph Kozole, Rachel Peltier-Heap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2011
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibitionAidan G Gilmartin, Maureen R Bleam, Arthur Groy, et al.
Structure (London, England : 1993)|April 13, 2016
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding PocketsGlenn S Van Aller, Alan P Graves, Patricia A Elkins, et al.
Angewandte Chemie (International Ed. in English)|August 4, 2020
A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein LigandsEmma K Grant, David J Fallon, Michael M Hann, et al.
Angewandte Chemie (International Ed. in English)|April 20, 2026
A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-EpimeraseWilliam M Browne, Jonathan Pettinger, Teresa Weckwerth, et al.
Chemistry & Biology|February 23, 2011
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding siteJingsong Yang, Nino Campobasso, Mangatt P Biju, et al.
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Cancer Discovery|April 8, 2024
Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer CellsGabriele Picco, Yanhua Rao, Angham Al Saedi, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Biomolecular Screening|October 29, 2013
Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cellsHu Li, Wensheng Xie, Elizabeth R Gore, et al.
Scientific Reports|December 18, 2020
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissuesPaul B Noto, Timothy W Sikorski, Francesca Zappacosta, et al.
Frontiers in Immunology|October 17, 2022
Complement membrane attack complex is an immunometabolic regulator of NLRP3 activation and IL-18 secretion in human macrophagesGisela Jimenez-Duran, Joseph Kozole, Rachel Peltier-Heap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2011
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibitionAidan G Gilmartin, Maureen R Bleam, Arthur Groy, et al.
Structure (London, England : 1993)|April 13, 2016
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding PocketsGlenn S Van Aller, Alan P Graves, Patricia A Elkins, et al.
Angewandte Chemie (International Ed. in English)|August 4, 2020
A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein LigandsEmma K Grant, David J Fallon, Michael M Hann, et al.
Angewandte Chemie (International Ed. in English)|April 20, 2026
A Synergistic Inhibitor Development Strategy Against Human UDP-Galactose-4-EpimeraseWilliam M Browne, Jonathan Pettinger, Teresa Weckwerth, et al.
Chemistry & Biology|February 23, 2011
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding siteJingsong Yang, Nino Campobasso, Mangatt P Biju, et al.
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Cancer Discovery|April 8, 2024
Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer CellsGabriele Picco, Yanhua Rao, Angham Al Saedi, et al.
Pageof 3